ABTI — Alterola Biotech Balance Sheet
0.000.00%
- $15.32m
- $15.56m
Annual balance sheet for Alterola Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | R2021 March 31st | R2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-Q | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | — | — | 0.001 | 0.064 | 0.009 |
Net Total Receivables | — | — | — | 0.051 | 0.038 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.015 | 0.015 | 0.001 | 0.265 | 0.237 |
Net Intangible Assets | |||||
Total Assets | 0.015 | 0.015 | 0.001 | 12.3 | 12.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.217 | 0.338 | 0.76 | 1.04 | 2.13 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.217 | 0.338 | 0.76 | 1.2 | 2.28 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.203 | -0.323 | -0.759 | 11.1 | 10.1 |
Total Liabilities & Shareholders' Equity | 0.015 | 0.015 | 0.001 | 12.3 | 12.4 |
Total Common Shares Outstanding |